increased risk of suicide-related events in this patient populations.Precautions:Not recommended for use during pregnancy, in nursing mothers. Epileptic patients, glaucoma, neuroleptic malignant syndrome, renal paroxetine en espanol hepatic impairment, activation of mania/hypomania, suicidal tendency, paroxetine en espanol paroxetine en espanol paroxetine en espanol heart disease.

of paroxetine to the elderly is paroxetine en espanol with increased plasma levels and prolongation of the elimination half-life relative to younger adults (see Pharmacology, Pharmacokinetics). Elderly paroxetine en espanol should be initiated and maintained at the paroxetine en espanol paroxetine en espanol dose of paroxetine which is associated with clinical efficacy.A paroxetine en espanol of 459 elderly patients (>=65 years) have participated in therapeutic studies with paroxetine. The pattern of adverse experiences in the elderly was paroxetine en espanol to that in younger patients.Children:The safety and effectiveness of paroxetine in children paroxetine en espanol 18 years of age have not been established.Pregnancy and Lactation:Although animal studies have not shown any teratogenic or selective embryotoxic effects, paroxetine en espanol safety of paroxetine paroxetine en espanol human paroxetine en espanol has not been established. Paroxetine should not be used during pregnancy unless the potential paroxetine en espanol paroxetine en espanol the patient outweighs the possible risk to the fetus.The concentrations paroxetine en espanol paroxetine en espanol detected paroxetine en espanol the paroxetine en espanol milk paroxetine en espanol paroxetine en espanol women are.

some subjects. Paroxetine has paroxetine en espanol reported to increase the systemic bioavailability of procyclidine.